Skip to content
Recovery & Performance PeptidesRecovery research and practical context
Source comparison

Research Evidence Base Comparison

From a published evidence standpoint, tesamorelin holds a substantially stronger position than either sermorelin or CJC-1295. The compound’s FDA approval was supported by two Phase III randomised controlled trials enrolling over 800 participants combined, with

This comparison does not assign a generated winner or score.

  • From a published evidence standpoint, tesamorelin holds a substantially stronger position than either sermorelin or CJC-1295. The compound’s FDA approval was supported by two Phase III randomised controlled trials enrolling over 800 participants combined, with standardised CT-based visceral fat endpoints and pre-specified safety monitoring. Sermorelin’s clinical evidence base is primarily from smaller Phase II studies and older investigations in paediatric GH deficiency rather than from large adult metabolic trials. CJC-1295 has been studied in Phase I and small Phase II investigations that documented GH and IGF-1 responses, but no large Phase III trials examining meaningful clinical outcomes such as body composition, metabolic markers, or cognitive endpoints have been published for this compound. This disparity in evidence quality is an important consideration in any research-oriented comparison of these compounds.
  • Source: Alba M, et al. (2006). Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone analog, normalizes growth hormone secretion in adults with GH deficiency. J Clin Endocrinol Metab. 91(6):2095–2102.